Research shows RSV leads to high hospitalization rates in adults, emphasizing the importance of enhanced surveillance and ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

Don’t let winter ailments slow you down. Discover how understanding your symptoms can lead to powerful relief while embracing ...

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Robert F. Kennedy Jr. had fired all 17 members of a key vaccine panel. Now his new panel recommended a new infant RSV vaccine ...

While respiratory syncytial virus (RSV) typically causes mild symptoms in adults, the virus can be life-threatening for infants. The seasonal virus is the most common cause of lower respiratory tract ...

The votes on vaccine recommendations are the first move by the panel after Health and Human Services Secretary Robert F.

Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

The CDC's newly reconstituted Advisory Committee on Immunization Practices (ACIP) voted 5-2 in support of infants younger ...

Federal vaccine advisors on Thursday recommended Merck's new RSV antibody shot for infants younger than eight months old in ...